559 reports of this reaction
4.0% of all FONDAPARINUX SODIUM reports
#2 most reported adverse reaction
HAEMATOMA is the #2 most commonly reported adverse reaction for FONDAPARINUX SODIUM, manufactured by Mylan Institutional LLC. There are 559 FDA adverse event reports linking FONDAPARINUX SODIUM to HAEMATOMA. This represents approximately 4.0% of all 13,905 adverse event reports for this drug.
Patients taking FONDAPARINUX SODIUM who experience haematoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOMA is moderately reported among FONDAPARINUX SODIUM users, representing a notable but not dominant share of adverse events.
In addition to haematoma, the following adverse reactions have been reported for FONDAPARINUX SODIUM:
The following drugs have also been linked to haematoma in FDA adverse event reports:
HAEMATOMA has been reported as an adverse event in 559 FDA reports for FONDAPARINUX SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOMA accounts for approximately 4.0% of all adverse event reports for FONDAPARINUX SODIUM, making it one of the most commonly reported side effect.
If you experience haematoma while taking FONDAPARINUX SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.